A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
Trial details
- Registry ID
- NCT07019922
- Drugs studied
- 0.5mg elsunersen, 1mg elsunersen
TrialRedline tracks 10 clinical trials sponsored by Praxis Precision Medicines: 5 Phase 3, 2 Phase 2 / 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyNCT07019922 | 0.5mg elsunersen, 1mg elsunersen | Recruiting | 2026-12Estimated |
| Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)NCT06087276 | 60 mg ulixacaltamide | Recruiting | 2025-10-10Actual |
| Clinical Trial of Vormatrigine in Adult Patients With EpilepsyNCT07287163 | vormatrogine | Enrolling by invitation | 2028-05-31Estimated |
| Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresNCT07505004 | 20 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 40 mg/day vormatrogine for 12 weeks | Active not recruiting | 2027-01Estimated |
| A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineNCT07010471 | 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562 | Active not recruiting | 2026-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)NCT05818553 | PRAX-562 | Active not recruiting | 2025-11-12Actual |
| Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)NCT06999902 | 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks | Completed | 2026-05-14Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic SeizuresNCT06908356 | 30mg PRAX-628 | Recruiting | 2025-07Estimated |
| A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential TremorNCT05021991 | 100 mg PRAX-944, 60 mg PRAX-944, Flexibly dosed 20 mg to 100 mg PRAX-944 | Completed | 2023-02-09Actual |
| A Clinical Trial of PRAX-944 in Participants With Essential TremorNCT05021978 | Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944 | Completed | 2022-03-24Actual |
Names as written in the registry records.
NCT06087276 · Praxis Precision Medicines
Before: Active not recruiting. After: Recruiting.
NCT06999902 · Praxis Precision Medicines
Before: Estimated. After: Actual.
Before: 230 participants (planned). After: 255 participants (actual).
Before: Estimated. After: Actual.
Before: 24 Nov 2025. After: 14 May 2026.
Before: Recruiting. After: Completed.
NCT07010471 · Praxis Precision Medicines
Before: Recruiting. After: Active not recruiting.
NCT07505004 · Praxis Precision Medicines
Before: Recruiting. After: Active not recruiting.
NCT07019922 · Praxis Precision Medicines
Before: Jun 2026. After: Dec 2026.
NCT06087276 · Praxis Precision Medicines
Before: Estimated. After: Actual.
Before: Sep 2025. After: 10 Oct 2025.
Before: Enrolling by invitation. After: Active not recruiting.
NCT07019922 · Praxis Precision Medicines
Before: 50 participants (planned). After: 40 participants (planned).
NCT07010471 · Praxis Precision Medicines
Before: Jul 2026. After: Dec 2026.
NCT05818553 · Praxis Precision Medicines
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To assess the effect of PRAX-562 on the frequency of countable motor seizures in pediatric participants with DEEs. After: Measure: PART A (Cohorts 1 and 2) RDB: To evaluate the safety and tolerability of PRAX 562 in pediatric participants with SCN2A- and SCN8A- DEEs Measure: PART B (Cohorts 1 and 2) OLE: To evaluate the long-term safety and tolerability of PRAX-562 in pediatric participants with DEEs.
Before: 100 participants (planned). After: 77 participants (planned).
Before: Estimated. After: Actual.
Before: 23 Mar 2026. After: 12 Nov 2025.
Before: Recruiting. After: Active not recruiting.